Sign In
Buy SLDB
$8.30
-0.0300 (-0.360%)
At Close: Jun 22, 2026
Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
08:00am, Thursday, 12'th Sep 2024
CHARLESTOWN, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neur
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 04'th Sep 2024
CHARLESTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and
Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates
04:08pm, Tuesday, 13'th Aug 2024
– Patients dosed in Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne); Dosing was well tolerated in all patients with initial data expected Q4 2
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:19pm, Monday, 01'st Jul 2024
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and c
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Tuesday, 04'th Jun 2024
CHARLESTOWN, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and c
3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off
06:00am, Monday, 20'th May 2024
Amid the rise of the digital innovation space, investors may want to consider biotech stocks to buy. Fundamentally, a rotation into the sector may occur, boding well for the ecosystem before the summe
SLDB Stock Earnings: Solid Biosciences Meets EPS for Q1 2024
12:53pm, Wednesday, 15'th May 2024
Solid Biosciences (NASDAQ: SLDB ) just reported results for the first quarter of 2024. Solid Biosciences reported earnings per share of -64 cents.
Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
07:52am, Wednesday, 15'th May 2024
— Received Rare Pediatric Disease and Orphan Drug Designation for Duchenne musculardystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trialexpected Q2 2024 —
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 02'nd May 2024
CHARLESTOWN, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and ca
Buy Solid Biosciences: Unpacking Its Main Value Driver
07:32pm, Wednesday, 10'th Apr 2024
Solid Biosciences is focused on gene therapy innovation for neuromuscular and cardiac conditions. Their flagship drug therapy for Duchenne muscular dystrophy (DMD) is expected to be tested in Q2 2024.
How this insider trader nailed every single stock trade
04:54am, Friday, 05'th Apr 2024
Sometimes, insider trading goes beyond just trading based on confidential information. It involves manipulating information for profit while also sharing it with others, causing significant impacts on
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 03'rd Apr 2024
CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, to
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
11:36am, Tuesday, 02'nd Apr 2024
Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.
– SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. – – Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 – CHARLESTOWN, M
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback
11:31am, Thursday, 28'th Mar 2024
Solid Biosciences is shrugging off several messy years in gene therapy development. The biotech stock has gotten a triple-digit boost.
